Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.
Medscape Medical News
source https://www.medscape.com/viewarticle/998373?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/998373?src=rss
Comments
Post a Comment